Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.43 USD | -1.23% | +1.58% | -26.68% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Financials (USD)
Sales 2024 * | 357M | Sales 2025 * | 403M | Capitalization | 949M |
---|---|---|---|---|---|
Net income 2024 * | 43M | Net income 2025 * | 56M | EV / Sales 2024 * | 2.66 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.35 x |
P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
16.5
x | Employees | 895 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.84% |
Latest transcript on MiMedx Group, Inc.
1 day | -1.23% | ||
1 week | +1.58% | ||
Current month | -16.49% | ||
1 month | -20.02% | ||
3 months | -20.52% | ||
6 months | +3.21% | ||
Current year | -26.68% |
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 6.43 | -1.23% | 648,215 |
24-04-23 | 6.51 | +2.36% | 747,532 |
24-04-22 | 6.36 | +1.11% | 623,570 |
24-04-19 | 6.29 | +2.11% | 691,192 |
24-04-18 | 6.16 | -2.69% | 542,394 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.68% | 949M | |
-18.52% | 131M | |
+7.32% | 60.9M | |
-15.34% | 61.96M | |
+1.20% | 52.2M |
- Stock Market
- Equities
- MDXG Stock